AC Immune Third Quarter 2026 Financial and Corporate Update
Positive clinical and regulatory progress achieved across wholly-owned pipeline
- ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND) clearance, and reported positive Part 1 week-100 results from the Phase 2 VacSYn trial in Parkinson’s disease
- Positive interim safety and tolerability results from the Phase 1 trial of NLRP3 inhibitor ACI-19764 in healthy volunteers
- Lead candidate declared in Morphomer® small molecule program targeting intracellular alpha-synuclein (a-syn)
- Further clinical data anticipated before year-end for ACI-7104 and early in 2027 for ACI-19764
- Cash resources of CHF 73.9 million as of September 30, 2026, providing cash runway into Q1 2028
Lausanne, Switzerland, November 4, 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharma company targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases, today provided financial and corporate updates for the quarter ended September 30, 2026.
